Calidi Biotherapeutics, Inc. Payments to Acquire Restricted Investments
Calidi Biotherapeutics, Inc. (CLDI) reported Payments to Acquire Restricted Investments of $1.34 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-21.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireRestrictedInvestments · last filed 2023-08-21
- Calidi Biotherapeutics, Inc. payments to acquire restricted investments for the quarter ending 2023-06-30 was $916.75K.
- Calidi Biotherapeutics, Inc. payments to acquire restricted investments for the quarter ending 2023-03-31 was $425.85K.
- Calidi Biotherapeutics, Inc. payments to acquire restricted investments for the quarter ending 2023-03-14 was $415.63K.
- Calidi Biotherapeutics, Inc. payments to acquire restricted investments for the quarter ending 2022-06-30 was $0.00.
- Calidi Biotherapeutics, Inc. payments to acquire restricted investments for fiscal 2022 was $2.32M.
| Period end | Payments to Acquire Restricted Investments | Payments to Acquire Restricted Investments 3 month | Payments to Acquire Restricted Investments 6 month | Payments to Acquire Restricted Investments 9 month | Payments to Acquire Restricted Investments 12 month |
|---|---|---|---|---|---|
| 2023-06-30 | $916.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $1.34M 10-Q · filed 2023-08-21 | |||
| 2023-03-31 | $425.85K 10-Q · filed 2023-05-15 | ||||
| 2023-03-14 | $415.63K 10-Q · filed 2023-08-21 | ||||
| 2022-12-31 | $2.32M 10-K · filed 2023-03-31 | ||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $0.00 10-Q · filed 2023-08-21 | $0.00 derived: sum of 3 quarters · filed 2023-08-21 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $0.00 derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-31 | $230.00M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $230.00M 10-Q · filed 2022-11-14 | ||||
| 2021-09-14 | $230.00M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |